ABL1 and B-cell chronic lymphocytic leukemia: Despite practice changes in treatments, such as the introduction of tyrosine-kinase inhibitors for BCR::ABL1+ in chronic myeloid leukemia (CML), or Bruton tyrosine kinase (BTK) and BCL2 inhibitors for chronic lymphocytic leukemia (CLL), these longitudinal sample collections remain highly relevant for translational immunologic research.76